ライブラリ登録: Guest
Begell Digital Portal Begellデジタルライブラリー 電子書籍 ジャーナル 参考文献と会報 リサーチ集
Critical Reviews™ in Eukaryotic Gene Expression
インパクトファクター: 1.841 5年インパクトファクター: 1.927 SJR: 0.627 SNIP: 0.516 CiteScore™: 1.96

ISSN 印刷: 1045-4403
ISSN オンライン: 2162-6502

Critical Reviews™ in Eukaryotic Gene Expression

DOI: 10.1615/CritRevEukarGeneExpr.v5.i3-4.70
pages 365-383

Indirect and Direct Disruption of Transcriptional Regulation in Cancer: E2F and AML-1

Shari Meyers
Department of Tumor Cell Biology, St. Jude Children's Research Hospital, 332 N. Lauderdale, Memphis, TN 38105
Scott W. Hiebert
Department of Tumor Cell Biology, St. Jude Children's Research Hospital, 332 N. Lauderdale, Memphis, TN 38105

要約

The disruption of transcriptional regulatory circuits through the elimination of negative regulatory factors (tumor suppressors), the activation of positive acting factors (oncogenes), or when chimeric proteins result from chromosomal translocations, is likely a key event in multistep tumorigenesis. Here, using the transcription factors E2F and AML-1 as model systems, we discuss the disruption of coordinate transcriptional regulation in oncogenesis. E2F oncogenic signals are released when the pRb tumor suppressor is inactivated, and E2F activation may necessitate the coordinate inactivation of a second tumor suppressor, p53. AML-1 is the target of the (8;21) translocation, found in approximately 15% of acute myeloid leukemia (AML) cases, and the t(12;21), found in up to 30% of childhood B-cell acute lymphoblastic leukemias. The t(8;21) creates a fusion protein between AML-1 and a gene of unknown function, mtg8 (ETO), whereas the t(12:21) fuses the TEL (translocation-ets-leukemia) transcription factor to the N-terminus of AML-1. The inv(16), which is the most frequent anomaly found in AML, also targets AML-1, by fusing the gene that encodes AML-l's heterodimeric partner CBFβ to the smooth muscle myosin heavy chain gene MYH11. Thus, E2F and AML-1 provide excellent models for the disruption of transcriptional regulation in cancer.

キーワード: AML-l, E2F, DP-1, t(8, 21), t(12, 21), translocation

Articles with similar content:

C/EBPα Dysregulation in AML and ALL
Critical Reviews™ in Oncogenesis, Vol.16, 2011, issue 1-2
Alan Friedman, Ido Paz-Priel
AML1-ETO—Mediated Erythroid Inhibition: New Paradigms for Differentiation Blockade by a Leukemic Fusion Protein
Critical Reviews™ in Eukaryotic Gene Expression, Vol.15, 2005, issue 3
Kamaleldin E. Elagib, Adam N. Goldfarb, Youngjin Choi
Cross-Regulation Between WNT and NF-κB Signaling Pathways
Forum on Immunopathological Diseases and Therapeutics, Vol.1, 2010, issue 3
Qiang Du, David Geller
Combined Gene Expression and DNA Occupancy Profiling as a Strategy to Identify Therapeutic Target(s) in t(8;21) Acute Myeloid Leukemia
Critical Reviews™ in Eukaryotic Gene Expression, Vol.23, 2013, issue 2
Luke F. Peterson, Miao-Chia Lo
Biological and Clinical Significance of Human NKRP1A/LLT1 Receptor/Ligand Interactions
Critical Reviews™ in Immunology, Vol.38, 2018, issue 6
Jacek Malejczyk, Agata Bialoszewska